Poised to Deliver Breakthroughs in Oncology and CNS Bexion Pharmaceuticals is a mid-stage clinical company developing life-changing treatments in Oncology and CNS. The company’s lead compound, BXQ-350, is a novel S1P modulator. With our highly experienced biotech leadership team and expertise in Oncology, we are urgently progressing our pipeline to develop life-changing oncology therapies on our path to becoming a leading biotech/pharmaceutical company. To learn more about Bexion Pharmaceuticals, please visit Bexionpharma.com or call (859) 446-7386.